Discontinuing statin use in patients with advanced-stage cancer and other terminal illnesses may help improve patients’ quality of life without causing other adverse health effects, according to a new study led by researchers at the University of Colorado Anschutz Medical Campus and Duke University and funded by the National Institute of Nursing Research (NINR).

The finding, published in JAMA Internal Medicine on March 23, indicates that care for patients with advanced illness can be improved by discontinuing some therapies that are primarily preventive for other health concerns.

“There is an increasing evidence base that discontinuation of some therapies may be beneficial for selected patient populations,” the authors write. Jean Kutner, MD, MSPH, University of Colorado Cancer Center investigator and professor of medicine at the University of Colorado School of Medicine, is the first author of the research study and Amy Abernethy, MD, PHD, of the Center for Learning Health Care at the Duke Clinical Research Institute, is the corresponding author.

Read more.